Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 3/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 5/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.46 |
| ▸ | PLK1 | P53350 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 3/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | CCR3 | P51677 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5462921 | 0.88 | SMN1; SMN2 (0.55) | CNR2P2RX7PLK1CNR1 | |
| SCHEMBL5451287 | 0.86 | L3MBTL1 (0.54) | CNR2P2RX7PLK1CNR1 | |
| SCHEMBL5452999 | 0.86 | KMT2A (0.52) | CNR2P2RX7PLK1CNR1 | |
| SCHEMBL14411259 | 0.86 | SMN1; SMN2 (0.55) | CNR2P2RX7PLK1CNR1 | |
| SCHEMBL5455250 | 0.85 | CNR2 (0.48) | CNR2P2RX7PLK1CNR1 | |
| SCHEMBL14411123 | 0.78 | KDM4E (0.49) | KDM4EIDO1S1PR1HTTCNR2 | |
| SCHEMBL5453464 | 0.78 | ADRA1D (0.52) | CNR2P2RX7PLK1ADRA1D | |
| SCHEMBL5454221 | 0.77 | KDM4E (0.53) | KDM4EIDO1S1PR1CNR2CNR1 | |
| SCHEMBL5450951 | 0.77 | HTR7 (0.55) | KDM4EIDO1S1PR1CNR2CCR3 | |
| SCHEMBL5444289 | 0.77 | CHRM1 (0.51) | KDM4EIDO1S1PR1HTTCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | KDM4E 3327/4885IDO1 3073/4885S1PR1 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.